Ranbaxy Will Begin U.S. Sales Of Generic Nexium In 2014 Under Deal Ending Patent Litigation
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal demonstrates strength of AstraZeneca’s patents, analyst says.
You may also be interested in...
Nexium Generics: Ranbaxy’s Exclusivity Loss Is Teva’s Gain
Teva’s readiness for approval prompts FDA conclusion that Ranbaxy forfeited its rights to 180-day exclusivity for AstraZeneca’s proton pump inhibitor; Ranbaxy is still making its case in court, but episode is suggestive of FDA’s increasing emphasis on application quality.
Ranbaxy Could See Six-Year Earnings Surge With Recent Collaborations
Firm signs antibacterial, antifungal drug development deal with Merck with $100 million-plus potential for each target.
Ranbaxy Could See Six-Year Earnings Surge With Recent Collaborations
Firm signs antibacterial, antifungal drug development deal with Merck with $100 million-plus potential for each target.